Business Description
Bioxytran Inc
NAICS : 325412
SIC : 2834
ISIN : US09075D1028
Total Employee Number:
3Description
Bioxytran Inc is a clinical stage pharmaceutical company developing platform technologies in the fields of Glycovirology, Hypoxia and Degenerative Diseases to eliminate viruses and prolong lifespan using carbohydrate drug design. Bioxytran uses Galectin inhibitors to combat the virus, SARS-CoV-2. Glycovirology is a novel glycan-based platform technology. The concept involves using sugar-based drugs to block viruses. The company is developing an inventive platform of oxygen therapeutic treatments for hypoxic conditions and necrosis prevention.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.15 | |||||
Equity-to-Asset | -14.84 | |||||
Debt-to-Equity | -0.25 | |||||
Debt-to-EBITDA | -0.37 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -3.4 | |||||
3-Year EPS without NRI Growth Rate | 1.7 | |||||
3-Year FCF Growth Rate | 27.9 | |||||
3-Year Book Growth Rate | -2.9 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 46.75 | |||||
9-Day RSI | 47.67 | |||||
14-Day RSI | 47.33 | |||||
3-1 Month Momentum % | -24.53 | |||||
6-1 Month Momentum % | -46.67 | |||||
12-1 Month Momentum % | -69.5 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.03 | |||||
Quick Ratio | 0.03 | |||||
Cash Ratio | 0.03 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 4.3 | |||||
Shareholder Yield % | -4.2 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROA % | -914.18 | |||||
ROIC % | -146.23 | |||||
3-Year ROIIC % | -130.8 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-EBIT | -1.13 | |||||
EV-to-EBITDA | -1.13 | |||||
EV-to-FCF | -4.06 | |||||
Earnings Yield (Greenblatt) % | -88.5 | |||||
FCF Yield % | -34.84 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:BIXT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Bioxytran Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.035 | ||
| Beta | -2.1141 | ||
| 3-Year Sharpe Ratio | -0.21 | ||
| 3-Year Sortino Ratio | -0.37 | ||
| Volatility % | 62.39 | ||
| 14-Day RSI | 47.33 | ||
| 14-Day ATR ($) | 0.002199 | ||
| 20-Day SMA ($) | 0.023136 | ||
| 12-1 Month Momentum % | -69.5 | ||
| 52-Week Range ($) | 0.0201 - 0.0949 | ||
| Shares Outstanding (Mil) | 114.7 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Bioxytran Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Bioxytran Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 75 days | ||
| General meeting for 2025 | 2026-08-31 | In 1 day | ||
| Second quarter earnings results for 2026 | 2026-08-14 | 0.02 (-5.68%) | ||
| First quarter earnings results for 2026 | 2026-05-15 | 0.03 (+0.00%) | ||
| Annual report for 2025 | 2026-04-15 | 0.04 (-0.26%) | ||
| Noble Capital Markets\' Emerging Growth Virtual Equity Conference | 2026-02-05 | 0.05 (+17.03%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 0.07 (+7.37%) | ||
| Second quarter earnings results for 2025 | 2025-08-11 | 0.08 (+0.00%) | ||
| First quarter earnings results for 2025 | 2025-05-15 | 0.10 (-12.89%) | ||
| Annual report for 2024 | 2025-04-03 | 0.15 (-4.22%) |
Show
Entries
Bioxytran Inc Frequently Asked Questions
What is Bioxytran Inc(BIXT)'s stock price today?
The current price of BIXT is $0.02. The 52 week high of BIXT is $0.09 and 52 week low is $0.02.
When is next earnings date of Bioxytran Inc(BIXT)?
The next earnings date of Bioxytran Inc(BIXT) is 2026-11-13 Est..
Does Bioxytran Inc(BIXT) pay dividends? If so, how much?
Bioxytran Inc(BIXT) does not pay dividend.
Press Release
Articles on Bioxytran Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers